Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3963 Target Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase · SINGLE PROTEIN · Plasmodium berghei str. ANKA

36Compounds
10Assays
1Approved Drugs
43.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q27713. Use UniProt Q27713 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q27713 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL3963, mapped to UniProt Q27713. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional dihydrofolate reductase-thymidylate synthase
SINGLE PROTEIN · Plasmodium berghei str. ANKA
As of 2026-09-14
ChEMBL target ID
CHEMBL3963
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q27713
Bifunctional dihydrofolate reductase-thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional dihydrofolate reductase-thymidylate synthase is the right protein anchor across sources, using UniProt Q27713 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional dihydrofolate reductase-thymidylate synthase
UniProt AccessionQ27713
Component TypeProtein
Sequence Length587 aa

Bifunctional dihydrofolate reductase-thymidylate synthase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt Q27713. Sequence length is 587 aa.

Mapped IDQ27713
Review nameBifunctional dihydrofolate reductase-thymidylate synthase
OrganismPlasmodium berghei str. ANKA
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5043.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL23746 8.24 IC50 5.7 Preclinical
CHEMBL440334 8.24 IC50 5.8 Preclinical
CHEMBL116183 8.12 IC50 7.5 Preclinical
CHEMBL118877 8.0 IC50 10.0 Preclinical
CHEMBL279455 8.0 IC50 10.0 Preclinical
CHEMBL23250 7.92 IC50 12.1 Preclinical
CHEMBL61857 7.92 IC50 12.0 Preclinical
CHEMBL24374 7.89 IC50 13.0 Preclinical
CHEMBL25888 7.82 IC50 15.0 Preclinical
CHEMBL26337 7.7 IC50 20.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
1
5.5
5
6.0
13
6.5
9
7.0
8
7.5
5
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRIMETHOPRIM
CHEMBL22
Approved 1973
Assay Landscape

Assay Landscape

10
Total Assays
35
Tested Compounds
1
Assay Types
Binding — 10 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 10 35 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine